Serina Therapeutics to merge with subsidiary of AgeX

31 Aug 2023
www.pharmaceutical-technology.com
Phase 1AcquisitionIND
Serina Therapeutics to merge with subsidiary of AgeX
Preview
Source: Pharmaceutical Technology
The combined company will focus on advancing Serina’s SER-227 for treating advanced Parkinson’s disease. Credit: Ground Picture/Shutterstock.com.
US-based clinical-stage biotechnology company Serina Therapeutics has entered an agreement to merge with AgeX Therapeutics’ wholly-owned subsidiary.
Serina’s stockholders will receive AgeX common stock shares and the combined company will continue under the name Serina Therapeutics.
Recommended Reports
Serina Therapeutics to merge with subsidiary of AgeX
Preview
Source: Pharmaceutical Technology
ReportsMergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry - Implic... GlobalData
Serina Therapeutics to merge with subsidiary of AgeX
Preview
Source: Pharmaceutical Technology
ReportsGlobal Mergers and Acquisitions (M&A) Deals in Pharma 2021 - Thematic Research GlobalData
View allCompanies IntelligenceAgeX Therapeutics IncSerina Therapeutics IncJuvenescence UK LtdAgex Pty LtdView all
It will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-227 (POZ-buprenorphine) for treating advanced Parkinson’s disease.
The aim is to submit an investigational new drug (IND) application to the US Food and Drug Administration to commence a Phase I trial in the fourth quarter of 2024.
The combined company will also expand Serina’s lipid nanoparticles and antibody drug conjugates by collaborating with other partners.
Serina Therapeutics board chair and co-founder Milton Harris stated: “The merger with AgeX positions Serina to advance our CNS pipeline assets and expand our platform partnering opportunities.
“We believe it represents the best path forward for Serina in accessing transformative capital to advance our platform technology.
“As a board director of the combined company, I look forward to collaborating with our new partners AgeX and Juvenescence, as we continue the work of translating our science into innovative therapeutics.”
The merger will conclude in the first quarter of 2024.
Pre-merger AgeX stockholders will own 25% of the new combined entity while pre-merger Serina stockholders will own 75%.
Serina is planning to submit IND applications for SER-227 for post-operative pain indications and for SER-228 (POZ-cannabidiol) for refractory epilepsy indications.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.